Mr. Wang Lin (王 琳), a non-executive Director of our company. He is primarily responsible for overseeing the management and operations of our Group.

From May 1997 to September 1998, Mr. Wang served as a project manager’s assistant and subcontract manager of Sinopec Engineering Incorporation (中国石化工程建设有限公司), a company principally engaged in engineering construction, where he was primarily responsible for project management. From November 2003 to July 2005, Mr. Wang served as business development and marketing manager of Eli Lilly Asia Inc. (美国礼来亚洲公司), a company principally engaged in development and sales of pharmaceutical products, where he was primarily responsible for business development and marketing affairs. From August 2005 to February 2009, Mr. Wang served as a project manager of McKinsey & Company, a company principally engaged in management consulting services, where he was primarily responsible for project management. From February 2009 to February 2011, Mr. Wang served as a vice president of Zhejiang Hisun Pharmaceutical Co., Ltd. (浙江海正药业股份有限公司), a pharmaceutical company whose shares are listed on the Shanghai Stock Exchange (stock code: 600267), where he was primarily responsible for business development and sales. From April 2011 to October 2013, Mr. Wang served as the strategic investment development director of China Resources Pharmaceutical Holdings Company Limited (华润医药控股有限公司), a subsidiary of China Resources Pharmaceutical Group Limited (华润医药集团有限公司), a pharmaceutical company whose shares are listed on the Hong Kong Stock Exchange (stock code: 3320) and general manager of Huarun Pien Tze Huang Pharmaceutical Co., Ltd. (华润片仔癀药业有限公司) (now known as Fujian Pien Tze Huang Health Technology co., Ltd. (福建片仔癀健康科技有限公司), a pharmaceutical company, respectively, where he was primarily responsible for the overall management. From October 2013 to January 2015, Mr. Wang served as a partner of Trustbridge Partners (摯信资本), a company principally engaged in investment and management consulting services, where Mr. Wang was primarily responsible for healthcare practice. From January 2015 to March 2017, he served as the general manager of Beijing Rogrand E-Commerce Co., Ltd. (北京融贯点子商务有限公司), a company principally engaged in operating ecommerce platform for pharmaceutical products, where he was primarily responsible for its overall management. From March 2018 to April 2019, he served as the co-president of Shanghai Tianyi Investment (Group) Co., Ltd. (上海天亿实业控股集团有限公司), a company principally engaged in investment and management of healthcare related companies, where he was primarily responsible for investment management. Since April 2019, he has been serving as a consultant to companies regarding strategy and investment matters.

Mr. Wang graduated from Tianjin University (天津大学) in the PRC with a bachelor’s degree in managerial engineering in July 1994. He received his master’s degree in business administration in the China Europe International Business School (中欧国际工商学院) in the PRC April 2003.